Menashe Levy is an entrepreneur, with over 20 years of product development experience and successful track record in progressing new technologies from an idea to advanced clinical development and global commercial stages.
Prior to co-founding Clexio, Menashe served in a variety of executive roles and as cofounder in innovation-driven, successful biotech and combo device-drug companies.
Prior to joining Clexio, Menashe was the CTO of Teva Pharmaceutical Global R&D. Before that, as VP for R&D at Aposense, he led the development of rationally-designed, small molecules for treatment of multiple disease categories. Previously, as VP for R&D at Regentis Biomaterials he led the development of GelrinC® (CE Mark) , a hydrogel implantable scaffold for cartilage regeneration . Formerly, he held the position of VP R&D at ColBar Lifesience that developed Evolence® dermal fillers line and OSSIXS® dental line, that were globally commercialized . Following the acquisition of Colbar by J&J, he served as VP for medical relationships and life cycle management at J&J consumer division. Earlier, he served as CTO of Rostam Ltd. and as a cofounder and CEO of its daughter company, HiGienic Intravaginal Technologies Ltd, which developed and commercialized the first, FDA approved, tampon drug delivery product. Menashe was also co-founder and VP of R&D and Operations of Gamida-Cell Ltd, where he led the development of StemEx®, an expanded stem/progenitor cells graft, derived from umbilical cord blood.
Menashe holds a bachelor degree in Pharmacy and a Ph.D. in Pharmaceutical Sciences from the Hebrew University of Jerusalem, and completed his Post-doctoral fellowship in the pharmaceutical chemistry at the University of California, San Francisco.